SCHEMBL259086

SCHEMBL259086

NCCCCC(C(=O)O)N(C(=O)CN)C(=O)C(N)Cc1c[nH]cn1

nearest known ligand 0.34

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.34
CPB2 Q96IY4 3/20 0.33
CPB1 P15086 1/20 0.33
SLC15A2 Q16348 1/20 0.31
ITGB3 P05106 1/20 0.31
ITGA2B P08514 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5155910 0.99 GSR (0.33) GSRCPB2CPB1SLC15A2ITGB3
SCHEMBL3948451 0.92 GSR (0.37) GSRCPB2CPB1SLC15A2ITGB3
SCHEMBL5884482 0.91 GSR (0.38) GSRCPB2CPB1SLC15A2ITGB3
SCHEMBL15023743 0.91 GSR (0.35) GSRCPB2CPB1
SCHEMBL5598612 0.89 GSR (0.34) GSRCPB2CPB1ITGB3ITGA2B
SCHEMBL5598853 0.89 GSR (0.31) GSRCPB2CPB1
SCHEMBL11028922 0.89 CYP1A2 (0.32)
SCHEMBL1959818 0.88 CPB2 (0.33) GSRCPB2CPB1ITGB3ITGA2B
SCHEMBL8781595 0.88 CPB2 (0.33) GSRCPB2CPB1
SCHEMBL29271692 0.87 ALOX15 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 361 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026040002-A1 COMPOSITION AND METHOD FOR CARING FOR THE SKIN L'OREAL (FR) 2026-02-26 WO claimed
CN-116919846-A Stem cell cytokine-containing composition and application thereof 国源细胞工程有限责任公司 2023-10-24 CN claimed
US-10905744-B2 Pharmaceutical formulations for the oral delivery of peptide drugs CYPRUMED GMBH (AT) 2021-02-02 US claimed
US-20180280481-A1 PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS CYPRUMED GMBH (AT) 2018-10-04 US claimed
CN-108135962-A For the pharmaceutical preparation of oral delivery peptide medicament 塞浦路迈德有限责任公司 2018-06-08 CN claimed
WO-2017060500-A1 PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS CYPRUMED GMBH (AT) 2017-04-13 WO claimed
EP-2059230-B1 TOPICAL USE OF A PEPTIDE EXTRACT OF SOYBEAN AND/OR OF WHEAT AS PHOTOPROTECTIVE AGENT THOREL JEAN-NOëL (FR) 2016-11-30 EP claimed
US-8865857-B2 Medical device with predefined activated cellular integration SOFRADIM PRODUCTION (FR) 2014-10-21 US claimed
EP-1594962-B1 COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS PROMEGA CORP (US) 2014-08-27 EP claimed
EP-2369006-B1 Covalent tethering of functional groups to proteins PROMEGA CORP (US) 2014-03-12 EP claimed
US-20070031516-A1 Composition for the prevention and treatment of cellulitis LIPOTEC, S.A. (ES) 2007-02-08 US claimed
CN-1767846-A Composition for preventing and treating cellulitis LIPOTEC SA (ES) 2006-05-03 CN claimed
JP-2006504448-A 2006-02-09 JP claimed
EP-1618125-A1 VITAMIN C DERIVATIVES WITH PEPTIDE, PREPARATION METHOD THEREOF AND COMPOSITION COMPRISING THE SAME Petron Co., Ltd. (KR) 2006-01-25 EP claimed
EP-1611898-A1 COMPOSITION FOR THE PREVENTION AND TREATMENT OF CELLULITIS LIPOTEC, S.A. (ES) 2006-01-04 EP claimed
EP-1534215-A1 COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND SOFT TISSUE FILLERS PROCYTE CORPORATION (US) 2005-06-01 EP claimed
WO-2004096837-A1 VITAMIN C DERIVATIVES WITH PEPTIDE, PREPARATION METHOD THEREOF AND COMPOSITION COMPRISING THE SAME PEPTRON CO., LTD (KR) 2004-11-11 WO claimed
WO-2004004671-A1 COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND SOFT TISSUE FILLERS PROCYTE CORPORATION (US) 2004-01-15 WO claimed
WO-1994018230-A1 INHIBITION OF HIV REPLICATION BY PEPTIDE-COPPER COMPLEXES PROCYTE CORPORATION (US) 1994-08-18 WO claimed
US-4732155-A Implantable chemoattractant system THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 1988-03-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180280481-A1 PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS SLC30A5, SLC39A11, SLC30A6 GSR 3160/4885CPB2 2279/4885CPB1 1572/4885
US-20070031516-A1 Composition for the prevention and treatment of cellulitis CUTA, LCT, LIPA GSR 1538/4885CPB2 2112/4885CPB1 2946/4885
US-10905744-B2 Pharmaceutical formulations for the oral delivery of peptide drugs SLC30A5, SLC39A11, SLC30A6 GSR 3160/4885CPB2 2279/4885CPB1 1572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.